American Medical Association Launches Its Own Vaccine Review Process
The American Medical Association (AMA), a medical trade advocacy association, is partnering with a vaccine research group to launch what it describes as an independent, “evidence-based review process” for respiratory vaccines for the next flu season—a role traditionally carried out by the U.S. Centers for Disease Control and Prevention (CDC).1 2 According to a prepared […]
Changes in Eye Health Linked to mRNA COVID-19 Shots
A recent prospective study published in 2025 in Ophthalmic Epidemiology has identified measurable changes in the cornea of the eye following receipt of mRNA COVID-19 biological, raising new questions about potential effects on eye health. Researchers observed differences in corneal thickness and endothelial cell characteristics in healthy adults after two doses of Pfizer/BioNTech’s Comirnaty COVID […]
Nipah Virus Cases in Asia Increase Pressure to Develop a Vaccine
On Jan. 26, 2026, the government of India confirmed two cases of Nipah virus (NiV) infection in its state of West Bengal. Both cases involved health care workers in a hospital in the district of North 24 Parganas. One of the individuals died after being hospitalized on Jan. 28. Contact tracing linked a total of […]
AAP Issues Its Own Recommended Childhood Vaccine Schedule
The American Academy of Pediatrics (AAP) has released its own recommended childhood vaccine guidance, breaking with updated recommendations issued earlier this month by the U.S. Centers for Disease Control and Prevention (CDC).1 On Jan. 6, 2026, the CDC formally updated the U.S. childhood vaccination schedule, introducing changes as to how vaccines are categorized and recommended. […]
Novavax Signs Licensing Agreement With Pfizer for Vaccine Adjuvant Technology
Novavax, Inc. and Pfizer, Inc. have signed a licensing arrangement allowing Pfizer access to Novavax’s Matrix-M adjuvant technology to boost immune response to vaccines. The agreement will allow for use in vaccines targeting up to two infectious diseases.1 Novavax’s Matrix-M technology is an aluminum-free adjuvant designed to enhance the immune response in protein-based vaccines such […]
FDA Requires Vaccine Makers to Include Febrile Seizure Warning on Flu Shot Labels
The U.S. Food and Drug Administration (FDA) notified six influenza vaccine manufacturers on Jan. 9, 2026 that they must add a warning about the risk of febrile (fever) seizures to their product information labels, citing newly identified postmarketing safety data. The notices, issued under the FDA’s statutory authority to mandate safety labeling changes, were sent […]